Date: 2015-07-30
Type of information: Clinical research agreement
Compound: regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics) studie
Company: AstraZeneca (UK) Charles River Laboratories International (USA)
Therapeutic area: Technology - Services
Type agreement: services
clinical research
Action mechanism:
Disease:
Details: Charles River Laboratories International has announced that it has been selected by AstraZeneca as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics). The three-year agreement extends into 2015. AstraZeneca began the process of transferring programs to Charles River earlier this year. This process is expected to be completed by early 2013. In 2013, the incremental sales under this agreement are expected to contribute approximately 1% to Charles River’s total net sales.
Financial terms:
Latest news: * On July 30, 2015, Charles River Laboratories announced that it has extended its initial three-year partnership with AstraZeneca for an additional five-year period. Under the agreement, which extends into 2020, Charles River retains its position as AstraZeneca’s preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).
